Literature DB >> 33893186

Metabolic Scar Assessment with18F-FDG PET: Correlation to Ischemic Ventricular Tachycardia Substrate and Successful Ablation Sites.

Yousra Ghzally, Hasan Imanli1,2, Mark Smith3, Jagat Mahat1, Wengen Chen1,4, Alejandro Jimenez1,2, Mariem A Sawan1,2, Mohamed Aboel-Kassem F Abdelmegid4, Hatem Abd El Rahman Helmy4, Salwa Demitry4, Vincent See1,2, Stephen Shorofsky1,2, Vasken Dilsizian3, Timm Dickfeld5,2.   

Abstract

The functional and molecular imaging characteristics of ischemic ventricular tachycardia (VT) substrate are incompletely understood. Our objective was to compare regional 18F-FDG PET tracer uptake with detailed electroanatomic maps (EAMs) in a more extensive series of postinfarction VT patients to define the metabolic properties of VT substrate and successful ablation sites.
Methods: Three-dimensional (3D) metabolic left ventricular reconstructions were created from perfusion-normalized 18F-FDG PET images in consecutive patients undergoing VT ablation. PET defects were classified as severe (defined as <50% uptake) or moderate (defined as 50%-70% uptake), as referenced to the maximal 17-segment uptake. Color-coded PET scar reconstructions were coregistered with corresponding high-resolution 3D EAMs, which were classified as indicating dense scarring (defined as voltage < 0.5 mV), normal myocardium (defined as voltage > 1.5 mV), or border zones (defined as voltage of 0.5-1.5 mV).
Results: All 56 patients had ischemic cardiomyopathy (ejection fraction, 29% ± 12%). Severe PET defects were larger than dense scarring, at 63.0 ± 48.4 cm2 versus 13.8 ± 33.1 cm2 (P < 0.001). Similarly, moderate/severe PET defects (≤70%) were larger than areas with abnormal voltage (≤1.5 mV) measuring 105.1 ± 67.2 cm2 versus 56.2 ± 62.6 cm2 (P < 0.001). Analysis of bipolar voltage (23,389 mapping points) showed decreased voltage among severe PET defects (n = 10,364; 0.5 ± 0.3 mV) and moderate PET defects (n = 5,243; 1.5 ± 0.9 mV, P < 0.01), with normal voltage among normal PET areas (>70% uptake) (n = 7,782, 3.2 ± 1.3 mV, P < 0.001). Eighty-eight percent of VT channel or exit sites (n = 44) were metabolically abnormal (severe PET defect, 78%; moderate PET defect, 10%), whereas 12% (n = 6) were in PET-normal areas. Metabolic channels (n = 26) existed in 45% (n = 25) of patients, with an average length and width of 17.6 ± 12.5 mm and 10.3 ± 4.2 mm, respectively. Metabolic channels were oriented predominantly in the apex or base (86%), harboring VT channel or exit sites in 31%. Metabolic rapid-transition areas (>50% change in 18F-FDG tracer uptake/15 mm) were detected in 59% of cases (n = 33), colocalizing to VT channels or exit sites (15%) or near these sites (85%, 12.8 ± 8.5 mm). Metabolism-voltage mismatches in which there was a severe PET defect but voltage indicating normal myocardium were seen in 21% of patients (n = 12), 41% of whom were harboring VT channel or exit sites.
Conclusion: Abnormal 18F-FDG uptake categories could be detected using incremental 3D step-up reconstructions. They predicted decreasing bipolar voltages and VT channel or exit sites in about 90% of cases. Additionally, functional imaging allowed detection of novel molecular tissue characteristics within the ischemic VT substrate such as metabolic channels, rapid-transition areas, and metabolism-voltage mismatches demonstrating intrasubstrate heterogeneity and providing possible targets for imaging-guided ablation.
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  18F-FDG PET imaging; VT channel or exit sites; functional imaging; ventricular tachycardia substrate

Mesh:

Substances:

Year:  2021        PMID: 33893186      PMCID: PMC8612320          DOI: 10.2967/jnumed.120.246413

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   11.082


  36 in total

1.  Three-dimensional contrast-enhanced multidetector CT for anatomic, dynamic, and perfusion characterization of abnormal myocardium to guide ventricular tachycardia ablations.

Authors:  Jing Tian; Jean Jeudy; Mark F Smith; Alejandro Jimenez; Xianghua Yin; Patricia A Bruce; Peng Lei; Aharon Turgeman; Aharon Abbo; Raj Shekhar; Magdi Saba; Stephen Shorofsky; Timm Dickfeld
Journal:  Circ Arrhythm Electrophysiol       Date:  2010-07-24

2.  MRI-Guided ventricular tachycardia ablation: integration of late gadolinium-enhanced 3D scar in patients with implantable cardioverter-defibrillators.

Authors:  Timm Dickfeld; Jing Tian; Ghada Ahmad; Alejandro Jimenez; Aharon Turgeman; Richard Kuk; Matthew Peters; Anastasios Saliaris; Magdi Saba; Stephen Shorofsky; Jean Jeudy
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-01-26

3.  Global and Regional Myocardial Innervation Before and After Ablation of Drug-Refractory Ventricular Tachycardia Assessed with 123I-MIBG.

Authors:  Mohammed Abdulghani; John Duell; Mark Smith; Wengen Chen; Søren M Bentzen; Ramazan Asoglu; Tomas Klein; Tamunoinemi Bob-Manuel; Anastasios Saliaris; Vincent See; Stephen Shorofsky; Vasken Dilsizian; Timm Dickfeld
Journal:  J Nucl Med       Date:  2015-06       Impact factor: 10.057

4.  ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures.

Authors:  Vasken Dilsizian; Stephen L Bacharach; Rob S Beanlands; Steven R Bergmann; Dominique Delbeke; Sharmila Dorbala; Robert J Gropler; Juhani Knuuti; Heinrich R Schelbert; Mark I Travin
Journal:  J Nucl Cardiol       Date:  2016-07-08       Impact factor: 5.952

5.  Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation.

Authors:  J M de Bakker; F J van Capelle; M J Janse; A A Wilde; R Coronel; A E Becker; K P Dingemans; N M van Hemel; R N Hauer
Journal:  Circulation       Date:  1988-03       Impact factor: 29.690

Review 6.  Substrate Mapping for Ventricular Tachycardia: Assumptions and Misconceptions.

Authors:  Mark E Josephson; Elad Anter
Journal:  JACC Clin Electrophysiol       Date:  2015-09-10

7.  Slow conduction in the infarcted human heart. 'Zigzag' course of activation.

Authors:  J M de Bakker; F J van Capelle; M J Janse; S Tasseron; J T Vermeulen; N de Jonge; J R Lahpor
Journal:  Circulation       Date:  1993-09       Impact factor: 29.690

8.  A swine model of infarct-related reentrant ventricular tachycardia: Electroanatomic, magnetic resonance, and histopathological characterization.

Authors:  Cory M Tschabrunn; Sébastien Roujol; Reza Nezafat; Beverly Faulkner-Jones; Alfred E Buxton; Mark E Josephson; Elad Anter
Journal:  Heart Rhythm       Date:  2015-07-28       Impact factor: 6.343

9.  Three-dimensional architecture of scar and conducting channels based on high resolution ce-CMR: insights for ventricular tachycardia ablation.

Authors:  Juan Fernández-Armenta; Antonio Berruezo; David Andreu; Oscar Camara; Etelvino Silva; Luis Serra; Valeria Barbarito; Luigi Carotenutto; Reinder Evertz; José T Ortiz-Pérez; Teresa María De Caralt; Rosario Jesús Perea; Marta Sitges; Lluis Mont; Alejandro Frangi; Josep Brugada
Journal:  Circ Arrhythm Electrophysiol       Date:  2013-05-17

10.  Radiofrequency catheter ablation of ventricular tachycardia in patients with coronary artery disease.

Authors:  F Morady; M Harvey; S J Kalbfleisch; R el-Atassi; H Calkins; J J Langberg
Journal:  Circulation       Date:  1993-02       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.